News

Supernus enters depression drug market with up to $795 million Sage deal
Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million, gaining access to the only ...
Sage, following Setbacks, to sell to Supernus for $561M
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...
GlobalData on MSN1d
Supernus makes depression drug play with $795m Sage buyout
After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...
BioSpace1d
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...
pharmaphorum1d
After rebuffing Biogen, Sage pairs off with Supernus
The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...
Fierce Pharma1d
Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae
Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...